# SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

> **NCT07230626** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 412 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** SYS6002
- **DRUG:** Investigator's Choice of Chemotherapy

## Key facts

- **NCT ID:** NCT07230626
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 412 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07230626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07230626, "SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07230626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*